Exagen to Announce Third Quarter 2019 Financial Results on November 12th, 2019
October 29 2019 - 8:00AM
Exagen Inc. (Nasdaq: XGN), an organization dedicated to
transforming the care continuum for patients suffering from
debilitating and chronic autoimmune diseases by enabling timely
differential diagnosis and optimizing therapeutic intervention,
today announced that it will release financial results for the
third quarter 2019 after the market closes on Tuesday, November
12th, 2019. Ron Rocca, President and Chief Executive Officer, and
Kamal Adawi, Chief Financial Officer, will host a conference call
to review the Company’s results at 4:30 PM Eastern Time (1:30 PM
Pacific Time).
Interested parties may access the conference call by dialing
(877) 407-3982 (U.S.) or (201) 493-6780 (international). Media and
individuals will be in a listen-only mode. Participants are asked
to dial in a few minutes prior to the call to register for the
event.
A replay of the conference call will be available until Tuesday,
November 19, 2019 at 11:59 PM Eastern Time (8:59 PM Pacific Time).
Interested parties may access the replay of the conference call by
dialing (844) 512-2921 (U.S.) or (412) 317-6671 (international)
using passcode 13695740.
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand, several of which are based on our proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable rheumatologists to improve care for
patients through the differential diagnosis, prognosis and
monitoring of complex autoimmune and autoimmune-related diseases,
including SLE and rheumatoid arthritis.
CONTACTS:
InvestorsWestwicke Partners Mike
CavanaughMike.Cavanaugh@westwicke.com646.677.1838
MediaExagen Inc. Brian
McEvillybmcevilly@exagen.com760.560.1506
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Sep 2023 to Sep 2024